Inference and forecasting phase shift regime of COVID-19 sub-lineages with a Markov-switching model. [PDF]
Noh E, Hong J, Yoo J, Jung J.
europepmc +1 more source
Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken +7 more
wiley +1 more source
Light does not phase shift the circadian clock of subcutaneous adipose tissue in vitro. [PDF]
Edmondson A, Beresford C, Harmsen JF.
europepmc +1 more source
Phase shift between joint rotation and actuation reflects dominant forces and predicts muscle activation patterns. [PDF]
Sutton GP +3 more
europepmc +1 more source
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
El Niño-driven phase shift to algal dominance on Isla del Caño's coral reefs: implications for urgent restoration. [PDF]
Palmer CV +2 more
europepmc +1 more source
Impact of Time-Restricted Feeding on Adaptation to a 6-Hour Delay Phase Shift or a 12-Hour Phase Shift in Mice. [PDF]
Ren B +7 more
europepmc +1 more source
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff +11 more
wiley +1 more source
Heterogeneous-IRS-Assisted Millimeter-Wave Systems: Element Position and Phase Shift Optimization. [PDF]
Zhao W, Wu Q, Wei H, Su D, Zhu Y.
europepmc +1 more source
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source

